580,000 shares of Dermapharma have been sold at a price of a €30per share

Dermapharma

Themis Beteiligungs-Aktiengesellschaft informed one of the top manufacturer of patent-free branded drugs for certain therapeutic areas in Germany with increasing international presence, Dermapharm Holding SE, that on 28th of June 580 thousand shares of Dermapharm for the price of 30 Euros per share have been vended outside a trading venue.

The 580 thousand shares are from the agreed Greenshoe option. Themis had gotten acquisition of these shares after the flotation on 9th February last year to stabilize the price.

After the sale, now the structure of the shareholder is composed as follows: At 75.05 percent (which was previously 76.13 percent), most of the no-par shares continue to be held by Themis. 24.95 percent (which was previously 23.87 percent) of the shares of Dermapharm are in free float.

For the time being, Dermapharm anticipates no further reduction in shares of Themis.

Discovered in 1991, Dermapharm is based in Grunwald and has its major manufacturing facility located in Brehna. The integrated business model of the firm comprises of in-house production, in-house development, and distribution of pharmaceuticals, as well as, other healthcare products for explicitly targeted markets by a pharmaceutical and medical sales force.

The firm holds around 900 marketing authorizations) for over 250 active pharmaceutical ingredients, which are marketed as dietary supplements, pharmaceuticals, or supplemental balanced diets. This variety makes the firm unique. Apart from Germany, the firm’s major markets also include Switzerland & Austria. The firm intends to further expand its international presence. Dermapharm’s business model is also inclusive of a parallel import business, which operates under the brand “axicorp”. Based on the revenues, Dermapharm was amongst the top five parallel import firms in Germany in 2018.

In the segment of ‘Herbal Extracts’, Dermapharm has access to the growing market for plant pharma in the Spanish firm Euromed S.A., one of the top manufacturers of plant-based active ingredients and plant extracts.